OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR

OBI Pharma (4174.TWO) continues to forge ahead on the global stage, recently debuting its innovative ThiOBI® platform and HYPrOBI™ linker technology at the American Association for Cancer Research (AACR) Annual Meeting. These two independently developed enabling technologies have greatly advanced next-generation antibody-drug conjugate (ADC) development capabilities, captivating attendees and drawing considerable interest and inquiries.